Diverse regulation of IP3 and ryanodine receptors by pentazocine through σ1-receptor in cardiomyocytes

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 8, 2013, Pages

  Tagashira, Hideaki ^a   Bhuiyan, Md Shenuarin ^b   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

1 receptor; ATP; Inositol 1,4,5 trisphosphate receptor; Myocardial hypertrophy; Pentazocine; Ryanodine receptor

Indexed keywords

2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; ADENOSINE TRIPHOSPHATE; CALCIUM; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; OPIATE RECEPTOR; PENTAZOCINE; RYANODINE RECEPTOR; ANGIOTENSIN II; ANISOLE DERIVATIVE; IP3R2 PROTEIN, MOUSE; N,N-DIPROPYL-2-(4-METHOXY-3-(2-PHENYLETHOXY)PHENYL)ETHYLAMINE MONOHYDROCHLORIDE; NARCOTIC AGENT; NARCOTIC ANTAGONIST; PROPYLAMINE; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR; VASOCONSTRICTOR AGENT; N,N DIPROPYL 2 (4 METHOXY 3 (2 PHENYLETHOXY)PHENYL)ETHYLAMINE MONOHYDROCHLORIDE; SIGMA 1 OPIATE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; RECEPTOR UPREGULATION; SARCOPLASMIC RETICULUM; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARDIOMEGALY; DRUG EFFECTS; HEART; HEART CONTRACTION; HEART LEFT VENTRICLE HYPERTROPHY; METABOLISM; OVARIECTOMY; PATHOPHYSIOLOGY; WISTAR RAT; Σ1 RECEPTOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; INOSITOL-1,4,5-TRISPHOSPHATE RECEPTOR;

ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; ANIMALS; ANISOLES; CALCIUM; CARDIOMEGALY; CELLS, CULTURED; FEMALE; HEART; HYPERTROPHY, LEFT VENTRICULAR; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; MITOCHONDRIA; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NARCOTIC ANTAGONISTS; NARCOTICS; OVARIECTOMY; PENTAZOCINE; PROPYLAMINES; RATS; RATS, WISTAR; RECEPTORS, SIGMA; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; VASOCONSTRICTOR AGENTS;

Σ1 RECEPTOR; ATP; INOSITOL-1,4,5-TRISPHOSPHATE RECEPTOR; MYOCARDIAL HYPERTROPHY; PENTAZOCINE; RYANODINE RECEPTOR;

EID: 84885614232     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00300.2013     Document Type: Article

References (34)

1. Ai X, Curran JW, Shannon TR, Bers DM, Pogwizd SM. Ca2 / calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca2 leak in heart failure. Circ Res 97: 1314-1322, 2005.
2. Bare DJ, Kettlun CS, Liang M, Bers DM, Mignery GA. Cardiac type 2 inositol 1,4,5-trisphosphate receptor: interaction and modulation by calcium/calmodulin-dependent protein kinase II. J Biol Chem 280: 15912-15920, 2005.
3. Benedict PE, Benedict MB, Su TP, Bolling SF. Opiate drugs and delta-receptor-mediated myocardial protection. Circulation 100: II357-II360, 1999.
4. Bhuiyan MS, Shioda N, Fukunaga K. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats. Am J Physiol Endocrinol Metab 293: E1606-E1614, 2007.
5. Bhuiyan MS, Shioda N, Shibuya M, Iwabuchi Y, Fukunaga K. Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension 53: 57-63, 2009.
6. Bhuiyan MS, Tagashira H, Fukunaga K. Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions. Expert Opin Ther Targets 14: 1009-1022, 2010.
7. Bolte C, Newman G, Schultz Jel J. Kappa and delta opioid receptor signaling is augmented in the failing heart. J Mol Cell Cardiol 47: 493-503, 2009.
8. Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. Sigma receptor ligands modulate contractility, Ca influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther 269: 1300-1309, 1994.
9. Gilbert PE, Martin WR. The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog. J Pharmacol Exp Ther 198: 66-82, 1976.
10. Go LO, Moschella MC, Watras J, Handa KK, Fyfe BS, Marks AR. Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J Clin Invest 95: 888-894, 1995.
11. 2 signaling and cell survival. Cell 131: 596-610, 2007.
12. Heinzel FR, MacQuaide N, Biesmans L, Sipido K. Dyssynchrony of Ca2 release from the sarcoplasmic reticulum as subcellular mechanism of cardiac contractile dysfunction. J Mol Cell Cardiol 50: 390-400, 2011.
13. Kannankeril PJ, Mitchell BM, Goonasekera SA, Chelu MG, Zhang W, Sood S, Kearney DL, Danila CI, De Biasi M, Wehrens XH, Pautler RG, Roden DM, Taffet GE, Dirksen RT, Anderson ME, Hamilton SL. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci USA 103: 12179-12184, 2006.
14. Kato R, Foëx P. Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists. Can J Anaesth 49: 777-791, 2002.
15. Kern KB. Postresuscitation myocardial dysfunction. Cardiol Clin 20: 89-101, 2002.
16. King CD, Goodin B, Glover TL, Riley JL, Hou W, Staud R, Fillingim RB. Is the pain-reducing effect of opioid medication reliable? A psychophysical study of morphine and pentazocine analgesia. Pain 154: 476-483, 2013.
17. Li X, Zima AV, Sheikh F, Blatter LA, Chen J. Endothelin-1-induced arrhythmogenic Ca2 signaling is abolished in atrial myocytes of inositol1,4,5-trisphosphate (IP3)-receptor type 2-deficient mice. Circ Res 96: 1274-1281, 2005.
18. Lu YM, Shioda N, Han F, Moriguchi S, Kasahara J, Shirasaki Y, Qin ZH, Fukunaga K. Imbalance between CaM kinase II and calcineurin activities impairs caffeine-induced calcium release in hypertrophic cardiomyocytes. Biochem Pharmacol 74: 1727-1737, 2007.
19. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphineand nalorphinelike drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197: 517-532, 1976.
20. Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M, Yamagishi M, Mori H, Kangawa K, Kitamura S. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol 287: H2670-H2676, 2004.
21. Nagle RE, Pilcher J. Respiratory and circulatory effects of pentazocine. Review of analgesics used after myocardial infarction. Br Heart J 34: 244-251, 1972.
22. Nakayama H, Bodi I, Maillet M, DeSantiago J, Domeier TL, Mikoshiba K, Lorenz JN, Blatter LA, Bers DM, Molkentin JD. The IP3 receptor regulates cardiac hypertrophy in response to select stimuli. Circ Res 107: 659-666, 2010.
23. Novakova M, Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur J Pharmacol 286: 19-30, 1995.
24. Obara G, Toyohira Y, Inagaki H, Takahashi K, Horishita T, Kawasaki T, Ueno S, Tsutsui M, Sata T, Yanagihara N. Pentazocine inhibits norepinephrine transporter function by reducing its surface expression in bovine adrenal medullary cells. J Pharm Sci 121: 138-147, 2013.
25. Ohkusa T, Hisamatsu Y, Ueyama T, Kobayashi S, Yano M, Maekawa T, Matsuzaki M. Effects of dantrolene sodium on progression of left ventricular hypertrophy induced by pressure overload in rats. J Cardiovasc Pharmacol 31: 520-524, 1998.
26. Respress JL, van Oort RJ, Li N, Rolim N, Dixit SS, deAlmeida A, Voigt N, Lawrence WS, Skapura DG, Skårdal K, Wisløff U, Wieland T, Ai X, Pogwizd SM, Dobrev D, Wehrens XH. Role of RyR2 phosphorylation at S2814 during heart failure progression. Circ Res 110: 1474-1483, 2012.
27. Shan Y, Sun S, Yang X, Weil MH, Tang W. Opioid receptor agonist reduces myocardial ischemic injury when administered during early phase of myocardial ischemia. Resuscitation 81: 761-765, 2010.
28. Shioda N, Ishikawa K, Tagashira H, Ishizuka T, Yawo H, Fukunaga K. Expression of a truncated form of the endoplasmic reticulum chaperone protein, sigma-1 receptor, promotes mitochondrial energy depletion and apoptosis. J Biol Chem 287: 23318-23331, 2012.
29. Tagashira H, Bhuiyan MS, Shioda N, Fukunaga K. Distinct cardioprotective effects of 17-estradiol and dehydroepiandrosterone on pressureoverload-induced hypertrophy in ovariectomized female rats. Menopause 18: 1317-1326, 2011.
30. Tagashira H, Bhuiyan MS, Shioda N, Hasegawa H, Kanai H, Fukunaga K. 1 Receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice. Am J Physiol Heart Circ Physiol 299: H1535-H1545, 2010.
31. 2 mobilization and ATP production following cardiac hypertrophy. Biochim Biophys Acta 1830: 3082-3094, 2013.
32. van Oort RJ, Respress JL, Li N, Reynolds C, De Almeida AC, Skapura DG, De Windt LJ, Wehrens XH. Accelerated development of pressure overload-induced cardiac hypertrophy and dysfunction in an RyR2-R176Q knockin mouse model. Hypertension 55: 932-938, 2010.
33. Wu T, Dong P, Chen C, Yang J, Hou X. The myocardial protection of polarizing cardioplegia combined with delta-opioid receptor agonist in swine. Ann Thorac Surg 91: 1914-1920, 2011.
34. Zou Y, Liang Y, Gong H, Zhou N, Ma H, Guan A, Sun A, Wang P, Niu Y, Jiang H, Takano H, Toko H, Yao A, Takeshima H, Akazawa H, Shiojima I, Wang Y, Komuro I, Ge J. Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy. Hypertension 58: 1099-1110, 2011.